Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

This study investigates whether adding magnesium to the standard chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC) can improve treatment outcomes. Magnesium is important for immune function, and low levels during chemotherapy are common. Participants are randomly assigned to receive either magnesium or a placebo, both as infusions and tablets. Neither the participants nor the doctors know who receives which treatment. The study compares the two groups to see if magnesium helps and how well it is tolerated.

Trial Details

NCT ID
NCT07149649
Phase
PHASE2 / PHASE3
Sponsor
Swiss Cancer Institute
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Magnesiocard
  • Magnesium Diasporal
  • Microcrystalline cellulose
  • Isotonic saline solution 0.9%
Locations (sample)
  • Aarau, Switzerland|47.39254,8.04422
  • Aarau, Switzerland|47.39254,8.04422
  • Baden, Switzerland|47.47333,8.30592
  • Basel, Switzerland|47.55839,7.57327
  • Basel, Switzerland|47.55839,7.57327

Key Eligibility Criteria

  • Written informed consent according to Swiss law and ICH GCP E6 regulations before registration and prior to any trial specific procedures;
  • Histologically or cytologically confirmed diagnosis of NSCLC (adeno-, squamous-, large cell carcinoma or NSCLC not otherwise specified);
  • Patients planned for systemic first-line therapy with a combination of a carboplatin-based doublet chemotherapy and a PD-1 / PD-L1 targeting immune…
  • Patients not eligible for immune checkpoint inhibitor monotherapy irrespective of PD-L1 expression;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →